Affordable Access

Access to the full text

Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates

Authors
  • Gauvain, Gregory1
  • Akolkar, Himanshu1, 2
  • Chaffiol, Antoine1
  • Arcizet, Fabrice1
  • Khoei, Mina A.1
  • Desrosiers, Mélissa1
  • Jaillard, Céline1
  • Caplette, Romain1
  • Marre, Olivier1
  • Bertin, Stéphane3
  • Fovet, Claire-Maelle4
  • Demilly, Joanna4
  • Forster, Valérie1
  • Brazhnikova, Elena1
  • Hantraye, Philippe4
  • Pouget, Pierre5
  • Douar, Anne6
  • Pruneau, Didier6
  • Chavas, Joël6
  • Sahel, José-Alain1, 2, 3
  • And 4 more
  • 1 Sorbonne Université, INSERM, CNRS, Institut de la Vision, 17 rue Moreau, Paris, F-75012, France , Paris (France)
  • 2 University Pittsburgh Medical Center, Pittsburgh, PA, USA , Pittsburgh (United States)
  • 3 CHNO des Quinze-Vingts, INSERM-DGOS CIC 1423, 28 rue de Charenton, Paris, F-75012, France , Paris (France)
  • 4 Institut d’imagerie Biomédicale (I2BM), Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Fontenay-aux–Roses, 92260, France , Fontenay-aux–Roses (France)
  • 5 ICM, UMRS 1127 UPMC – U 1127 INSERM – UMR 7225 CNRS, Paris, France , Paris (France)
  • 6 Gensight Biologics, 74 rue du faubourg Saint Antoine, Paris, F-75012, France , Paris (France)
Type
Published Article
Journal
Communications Biology
Publisher
Nature Publishing Group UK
Publication Date
Jan 27, 2021
Volume
4
Issue
1
Identifiers
DOI: 10.1038/s42003-020-01594-w
Source
Springer Nature
License
Green

Abstract

Gauvain et al demonstrate that optogenetic therapy using the AAV2.7m8- ChR-tdT construct can partially restore vision in non-human primates to levels above those considered legally-blind. This study enables the identification of the most suitable construct for ongoing clinical trials attempting vision restoration in patients with retinitis pigmentosa.

Report this publication

Statistics

Seen <100 times